New Immunotherapy Guidelines Will Help Clinicians Treat Lung Cancer
After the FDA approved Opdivo to treat non-small cell lung cancer (NSCLC) in March of 2015, it replaced cytotoxic chemotherapy as the main method of treatment for the disease. Immunotherapy has since become preferable to chemotherapy, as many new checkpoint inhibitors have also been FDA-approved. But because many immunotherapy treatments were introduced to the lab […]
Continue readingEuropean Committee Approves Opdivo Advance
Opdivo Advances in Europe In response to the decision made in the United States last March, manufacturer Bristol-Myers Squibb has announced a new dosing schedule for Opdivo (nivolumab), recommended by the Committee for Medicinal Products for Human Use of the European Medicines Agency. This new dosing schedule lets physicians choose to prescribe Opdivo as a […]
Continue reading